Journal
DIABETES & VASCULAR DISEASE RESEARCH
Volume 7, Issue 4, Pages 251-259Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164110383994
Keywords
Cardiovascular disease; diabetes mellitus; platelets
Funding
- Eli Lilly
- Daiichi Sankyo
- Bristol Myers Squibb
- Sanofi-Aventis
- Eli Lilly Co
- Daiichi Sankyo, Inc
- Medicines Company
- Portola
- Novartis
- Medicure
- Accumetrics
- Arena Pharmaceuticals
- Merck
- GlaxoSmithKline
- Otsuka
- Schering-Plough
Ask authors/readers for more resources
Patients with diabetes mellitus (DM) have accelerated atherosclerosis, which is the main underlying factor contributing to the high risk of atherothrombotic events in these patients Atherothrombotic complications are the leading cause of morbidity and mortality in patients with DM Among factors contributing to the prothrombotic condition which characterise patients with DM, platelet hyperreactivity plays a pivotal role Platelets of DM patients are characterised by dysregulation of several signalling pathways leading to intensified adhesion, activation and aggregation Multiple mechanisms are involved in platelet dysfunction of patients with DM, which can be categorised as follows a) hyperglycaemia, b) insulin deficiency and resistance, c) associated metabolic conditions, and d) other cellular abnormalities The present manuscript aims to provide an overview on the current status of knowledge on platelet abnormalities that characterise patients with DM
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available